ACT4RHD is an Open-label, Randomised, Adaptive Platform Trial to Evaluate Novel and Repurposed Clinical Interventions for Patients With Acute Rheumatic Fever and Carditis. ACT4RHD Seeks to Determine Whether These Interventions Reduce RHD Severity at 6 Months.
A phase 3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 600 participants.
Also called NCT07830108
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 600 participants
- Sponsor
- Registry
-
NCT07830108
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Australia, New Zealand
- Registry status
- Not yet recruiting
Technical summary
Registry record NCT07830108. Randomized; no masking; primary purpose treatment. Start 2026-12 (anticipated); primary completion 2034-12 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- ACT4RHD is an Open-label, Randomised, Adaptive Platform Trial to Evaluate Novel and Repurposed Clinical Interventions for Patients With Acute Rheumatic Fever and Carditis. ACT4RHD Seeks to Determine Whether These Interventions Reduce RHD Severity at 6 Months.
- Acronym
- ACT4RHD
- Condition
- Rheumatic Fever
- Condition
- Rheumatic Heart Disease in Children
- Condition
- Acute Rheumatic Fever
- Condition
- Rheumatic Heart Disease
- Intervention (Drug)
- Hydroxychloroquine (HCQ)
- Intervention (Other)
- No Hydroxychloroquine (HCQ)
- Intervention (Drug)
- Prednisone or Prednisolone
- Intervention (Other)
- No corticosteroid
- Lead sponsor
- Starship Child Health, Te Toka Tumai Auckland
- Collaborator
- Menzies School of Health Research
- Collaborator
- Berry Consultants
Record details
- Record id
cardio:ct-nct07830108- Content hash
7a15f70c93b946311a17a8188f64caa4ceb7d9ceca676a2d20500eaebd2a86ab